Filed Pursuant to
Rule 424(b)(3)
Registration Nos. 333-224424 and
333-225768
PROSPECTUS SUPPLEMENT
NO. 9
(TO
PROSPECTUS DATED JUNE 20, 2018, AS AMENDED JUNE 28,
2019)
INVIVO
THERAPEUTICS HOLDINGS CORP.
7,586,711 Warrants to purchase
shares of Common Stock
This prospectus
supplement No. 9 supplements and amends the prospectus dated
June 20, 2018, as amended June 28, 2019, and as
supplemented by prospectus supplement No.1, dated
September 28, 2018, prospectus supplement No. 2, dated
October 5, 2018, prospectus supplement No. 3, dated
November 8, 2018, prospectus supplement No. 4, dated
November 13,2018, prospectus supplement No.5, dated
November 16, 2018, prospectus supplement No.6, dated
December 14, 2018, prospectus supplement No. 7,
dated January 4, 2019, and prospectus supplement No. 8,
dated January 14, 2019, related to the sale or other
disposition from time to time of 7,586,711 warrants (the
“Warrants”) to purchase shares of common stock, par value $0.00001
per share (the “Common Stock”), of InVivo Therapeutics Holdings
Corp., a Nevada corporation (the “Company,” “we,” “us” or “our”)
issued to Ladenburg Thalmann & Co. Inc., the
underwriter named in the prospectus, also referred to as LTCO,
pursuant to an underwriting agreement dated June 21, 2018 that
we entered into with LTCO.
This prospectus
supplement should be read in conjunction with the prospectus dated
June 20, 2018, as amended June 28, 2019, which is to be
delivered with this prospectus supplement. This prospectus
supplement is qualified by reference to the prospectus except to
the extent that the information in this prospectus supplement
supersedes the information contained in the prospectus. This
prospectus supplement is not complete without, and may not be
delivered or utilized except in connection with, the prospectus,
including any amendments or supplements to it.
The Common Stock is
quoted on The Nasdaq Capital Market under the symbol “NVIV.” On
November 20, 2019, the last reported sale price of the Common
Stock on the Nasdaq Capital Market was $0.2327 per
share.
On November 20,
2019, we unilaterally reduced the per share exercise price of all
of the outstanding Warrants issued under this prospectus to $0.2327
per share, which was equal to the closing price of our Common Stock
on the Nasdaq Capital Market on November 20, 2019. The
reduction will be effective as of November 20, 2019. Other
than the reduction in the per share exercise price, all other terms
and provisions of the Warrants remain unchanged. Upon the exercise
of the Warrants, we would potentially receive proceeds of up to
approximately $1.8 million. There can be no assurance that the
Warrants will be exercised.
Investing in our common stock
involves risks. See “Risk Factors” beginning on page 10 of the
prospectus.
Neither the Securities
and Exchange Commission nor any state securities commission has
approved or disapproved of these securities or determined if this
prospectus supplement or the prospectus to which it relates are
truthful or complete. Any representation to the contrary is a
criminal offense.
The date of this
prospectus supplement is November 20, 2019.